Skip to contentG
Gilead Sciences, Inc.
G
GILDGilead Sciences, Inc. Source filing unavailable
Q3 2014 · —
Revenue$6.04B$6.04B+117.1% vs Q3 2013 Net Income$2.73B$2.73B+246.1% vs Q3 2013 EPS Diluted$1.67$1.67+255.3% vs Q3 2013 Gross Profit$4,981,000,000+145.6% Operating Income$3,480,000,000+203.2% Operating Cash Flowderived
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gilead Sciences, Inc. · CIK 882095 · Engraved from SEC EDGAR
Free Cash Flowderived$3,909,000,000+446.0% Margins · derivedGross margin82.4%+9.6 pt vs Q3 2013
Operating margin57.6%+16.4 pt vs Q3 2013
Net margin45.2%+16.8 pt vs Q3 2013